On the Structure and functions of gelatinase B/Matrix metalloproteinase-9 in neuroinflammation

Progress in Brain Research

Volumn 214, Issue , 2014, Pages 193-206

  Vandooren, Jennifer ^a   Van Damme, Jo ^a   Opdenakker, Ghislain ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

MMP 2; MMP 9; Multiple sclerosis; Neuroinflammation; TIMP 1

Indexed keywords

BETA DYSTROGLYCAN; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE INHIBITOR; MONOMER; POLYMER; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; AUTOIMMUNITY; BASEMENT MEMBRANE; BLOOD BRAIN BARRIER; ENZYME STRUCTURE; HUMAN; MEMBRANE DAMAGE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROBIOLOGY; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; ZYMOGRAPHY;

EID: 84922322478     PISSN: 00796123     EISSN: 18757855     Source Type: Book Series    
DOI: 10.1016/B978-0-444-63486-3.00009-8     Document Type: Chapter

References (64)

1. Agrawal S., Anderson P., Durbeej M., van Rooijen N., Ivars F., Opdenakker G., Sorokin L.M. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J. Exp. Med. 2006, 203:1007-1019.
2. Cauwe B., Opdenakker G. Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit. Rev. Biochem. Mol. Biol. 2010, 45:351-423.
3. Cauwe B., Van den Steen P.E., Opdenakker G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit. Rev. Biochem. Mol. Biol. 2007, 42:113-185.
4. Cha H., Kopetzki E., Huber R., Lanzendorfer M., Brandstetter H. Structural basis of the adaptive molecular recognition by MMP9. J. Mol. Biol. 2002, 320:1065-1079.
5. Collier I.E., Legant W., Marmer B., Lubman O., Saffarian S., Wakatsuki T., Elson E., Goldberg G.I. Diffusion of MMPs on the surface of collagen fibrils: the mobile cell surface-collagen substratum interface. PLoS One 2011, 6:e24029.
6. Creighton C., Hanash S. Expression of matrix metalloproteinase 9 (MMP-9/gelatinase B) in adenocarcinomas strongly correlated with expression of immune response genes. In Silico Biol. 2003, 3:301-311.
7. Descamps F.J., Martens E., Opdenakker G. Analysis of gelatinases in complex biological fluids and tissue extracts. Lab. Invest. 2002, 82:1607-1608.
8. Descamps F.J., Martens E., Proost P., Starckx S., Van den Steen P.E., Van Damme J., Opdenakker G. Gelatinase B/matrix metalloproteinase-9 provokes cataract by cleaving lens betaB1 crystallin. FASEB J. 2005, 19:29-35.
9. D'Haese A., Wuyts A., Dillen C., Dubois B., Billiau A., Heremans H., Van Damme J., Arnold B., Opdenakker G. In vivo neutrophil recruitment by granulocyte chemotactic protein-2 is assisted by gelatinase B/MMP-9 in the mouse. J. Interferon Cytokine Res. 2000, 20:667-674.
10. Di Girolamo N., Tedla N., Lloyd A., Wakefield D. Expression of matrix metalloproteinases by human plasma cells and B lymphocytes. Eur. J. Immunol. 1998, 28:1773-1784.
11. Dubois B., Masure S., Hurtenbach U., Paemen L., Heremans H., van den Oord J., Sciot R., Meinhardt T., Hämmerling G., Opdenakker G., Arnold B. Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J. Clin. Invest. 1999, 104:1507-1515.
12. Dufour A., Zucker S., Sampson N.S., Kuscu C., Cao J. Role of matrix metalloproteinase-9 dimers in cell migration: design of inhibitory peptides. J. Biol. Chem. 2010, 285:35944-35956.
13. Elkins P.A., Ho Y.S., Smith W.W., Janson C.A., D'Alessio K.J., McQueney M.S., Cummings M.D., Romanic A.M. Structure of the C-terminally truncated human ProMMP9, a gelatin-binding matrix metalloproteinase. Acta Crystallogr. D Biol. Crystallogr. 2002, 58:1182-1192.
14. Farina A.R., Mackay A.R. Gelatinase B/MMP-9 in tumour pathogenesis and progression. Cancers 2014, 6:240-296.
15. Geurts N., Becker-Pauly C., Martens E., Proost P., Van den Steen P.E., Stöcker W., Opdenakker G. Meprins process matrix metalloproteinase-9 (MMP-9)/gelatinase B and enhance the activation kinetics by MMP-3. FEBS Lett. 2012, 586:4264-4269.
16. Gijbels K., Masure S., Carton H., Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J. Neuroimmunol. 1992, 41:29-34.
17. Gijbels K., Proost P., Masure S., Carton H., Billiau A., Opdenakker G. Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J. Neurosci. Res. 1993, 36:432-440.
18. Goldberg G.I., Strongin A., Collier I.E., Genrich L.T., Marmer B.L. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J. Biol. Chem. 1992, 267:4583-4591.
19. Grillet B., Dequeker J., Paemen L., Van Damme B., Opdenakker G. Gelatinase B in chronic synovitis: immunolocalization with a monoclonal antibody. Br. J. Rheumatol. 1997, 36:744-747.
20. Hayashi M., Schellenberg R.R., Tsang S., Roberts C.R. Matrix metalloproteinase-9 in myeloid cells: implications for allergic inflammation. Int. Arch. Allergy Immunol. 1999, 118:429-432.
21. Hu J., Van den Steen P.E., Sang Q.X., Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discov. 2007, 6:480-498.
22. Itoh T., Matsuda H., Tanioka M., Kuwabara K., Itohara S., Suzuki R. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J. Immunol. 2002, 169:2643-2647.
23. Liechti F.D., Grandgirard D., Leppert D., Leib S.L. Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect. Immun. 2014, 82:1710-1718.
24. Liotta L. The role of cellular proteases and their inhibitors in invasion and metastasis. Introductionary overview. Cancer Metastasis Rev. 1990, 9:285-287.
25. Masure S., Proost P., Van Damme J., Opdenakker G. Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8. Eur. J. Biochem. 1991, 198:391-398.
26. Mattu T.S., Royle L., Langridge J., Wormald M.R., Van den Steen P.E., Van Damme J., Opdenakker G., Harvey D.J., Dwek R.A., Rudd P.M. O-glycan analysis of natural human neutrophil gelatinase B using a combination of normal phase-HPLC and online tandem mass spectrometry: implications for the domain organization of the enzyme. Biochemistry 2000, 39:15695-15704.
27. Montgomery A.M., Sabzevari H., Reisfeld R.A. Production and regulation of gelatinase B by human T-cells. Biochim. Biophys. Acta 1993, 1176:265-268.
28. Olson M.W., Bernardo M.M., Pietila M., Gervasi D.C., Toth M., Kotra L.P., Massova I., Mobashery S., Fridman R. Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9. Differential rates for activation by stromelysin 1. J. Biol. Chem. 2000, 275:2661-2668.
29. Opdenakker G., Van Damme J. Cytokine-regulated proteases in autoimmune diseases. Immunol. Today 1994, 15:103-107.
30. Opdenakker G., Van Damme J. Probing cytokines, chemokines and matrix metalloproteinases towards better immunotherapies of multiple sclerosis. Cytokine Growth Factor Rev. 2011, 22:359-365.
31. Opdenakker G., Bosman F., Decock B., Cabeza-Arvelaiz Y., Van Damme J., Billiau A. Heterogeneity of human tissue-type plasminogen activator. FEBS Lett. 1988, 238:129-134.
32. Opdenakker G., Masure S., Grillet B., Van Damme J. Cytokine-mediated regulation of human leukocyte gelatinases and role in arthritis. Lymphokine Cytokine Res. 1991, 10:317-324.
33. Opdenakker G., Masure S., Proost P., Billiau A., Van Damme J. Natural human monocyte gelatinase and its inhibitor. FEBS Lett. 1991, 284:73-78.
34. Opdenakker G., Van den Steen P.E., Dubois B., Nelissen I., Van Coillie E., Masure S., Proost P., Van Damme J. Gelatinase B functions as regulator and effector in leukocyte biology. J. Leukoc. Biol. 2001, 69:851-859.
35. Opdenakker G., Nelissen I., Van Damme J. Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis. Lancet Neurol. 2003, 2:747-756.
36. Paemen L., Olsson T., Söderström M., Van Damme J., Opdenakker G. Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases. Eur. J. Neurol. 1994, 1:55-63.
37. Paemen L., Martens E., Masure S., Opdenakker G. Monoclonal antibodies specific for natural human neutrophil gelatinase B used for affinity purification, quantitation by two-site ELISA and inhibition of enzymatic activity. Eur. J. Biochem. 1995, 234:759-765.
38. Proost P., Van Damme J., Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem. Biophys. Res. Commun. 1993, 192:1175-1181.
39. Redondo-Munoz J., Ugarte-Berzal E., Terol M.J., Van den Steen P.E., Hernandez del C.M., Roderfeld M., Roeb E., Opdenakker G., Garcia-Marco J.A., Garcia-Pardo A. Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia B cell survival through its hemopexin domain. Cancer Cell 2010, 17:160-172.
40. Rosenberg G.A. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol. 2009, 8:205-216.
41. Rosenblum G., Van den Steen P.E., Cohen S.R., Grossmann J.G., Frenkel J., Sertchook R., Slack N., Strange R.W., Opdenakker G., Sagi I. Insights into the structure and domain flexibility of full-length pro-matrix metalloproteinase-9/gelatinase B. Structure 2007, 15:1227-1236.
42. Rossano R., Larocca M., Riviello L., Coniglio M.G., Vandooren J., Liuzzi G.M., Opdenakker G., Riccio P. Heterogeneity of serum gelatinases MMP-2 and MMP-9 isoforms and charge variants. J. Cell. Mol. Med. 2014, 18:242-252.
43. Rudd P.M., Mattu T.S., Masure S., Bratt T., Van den Steen P.E., Wormald M.R., Kuster B., Harvey D.J., Borregaard N., Van Damme J., Dwek R.A., Opdenakker G. Glycosylation of natural human neutrophil gelatinase B and neutrophil gelatinase B-associated lipocalin. Biochemistry 1999, 38:13937-13950.
44. Schwingshackl A., Duszyk M., Brown N., Moqbel R. Human eosinophils release matrix metalloproteinase-9 on stimulation with TNF-alpha. J. Allergy Clin. Immunol. 1999, 104:983-989.
45. Shiryaev S.A., Remacle A.G., Savinov A.Y., Chernov A.V., Cieplak P., Radichev I.A., Williams R., Shiryaeva T.N., Gawlik K., Postnova T.I., Ratnikov B.I., Eroshkin A.M., Motamedchaboki K., Smith J.W., Strongin A.Y. Inflammatory proprotein convertase-matrix metalloproteinase proteolytic pathway in antigen-presenting cells as a step to autoimmune multiple sclerosis. J. Biol. Chem. 2009, 284:30615-30626.
46. Sorokin L. The impact of the extracellular matrix on inflammation. Nat. Rev. Immunol. 2010, 10:712-723.
47. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994, 76:301-314.
48. Starckx S., Van den Steen P.E., Verbeek R., van Noort J.M., Opdenakker G. A novel rationale for inhibition of gelatinase B in multiple sclerosis: MMP-9 destroys alpha B-crystallin and generates a promiscuous T cell epitope. J. Neuroimmunol. 2003, 141:47-57.
49. Stetler-Stevenson M., Mansoor A., Lim M., Fukushima P., Kehrl J., Marti G., Ptaszynski K., Wang J., Stetler-Stevenson W.G. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in reactive and neoplastic lymphoid cells. Blood 1997, 89:1708-1715.
50. Suzukawa M., Komiya A., Iikura M., Nagase H., Yoshimura-Uchiyama C., Yamada H., Kawasaki H., Ohta K., Matsushima K., Hirai K., Yamamoto K., Yamaguchi M. Trans-basement membrane migration of human basophils: role of matrix metalloproteinase-9. Int. Immunol. 2006, 18:1575-1583.
51. Van Damme J., De Ley M., Opdenakker G., Billiau A., De Somer P., Van Beeumen J. Homogeneous interferon-inducing 22K factor is related to endogenous pyrogen and interleukin-1. Nature 1985, 314:266-268.
52. Van Damme J., Opdenakker G., Simpson R.J., Rubira M.R., Cayphas S., Vink A., Billiau A., Van Snick J. Identification of the human 26-kD protein, interferon beta 2 (IFN-beta 2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor. J. Exp. Med. 1987, 165:914-919.
53. Van Damme J., Van Beeumen J., Opdenakker G., Billiau A. A novel, NH2-terminal sequence-characterized human monokine possessing neutrophil chemotactic, skin-reactive, and granulocytosis-promoting activity. J. Exp. Med. 1988, 167:1364-1376.
54. Van Damme J., Wuyts A., Froyen G., Van Coillie E., Struyf S., Billiau A., Proost P., Wang J.M., Opdenakker G. Granulocyte chemotactic protein-2 and related CXC chemokines: from gene regulation to receptor usage. J. Leukoc. Biol. 1997, 62:563-569.
55. Van den Steen P.E., Van Aelst I., Hvidberg V., Piccard H., Fiten P., Jacobsen C., Moestrup S.K., Fry S., Royle L., Wormald M.R., Wallis R., Rudd P.M., Dwek R.A., Opdenakker G. The hemopexin and O-glycosylated domains tune gelatinase B/MMP-9 bioavailability via inhibition and binding to cargo receptors. J. Biol. Chem. 2006, 281:18626-18637.
56. Van Ranst M., Norga K., Masure S., Proost P., Vandekerckhove F., Auwerx J., Van Damme J., Opdenakker G. The cytokine-protease connection: identification of a 96-kD THP-1 gelatinase and regulation by interleukin-1 and cytokine inducers. Cytokine 1991, 3:231-239.
57. Vandooren J., Geurts N., Martens E., Van den Steen P.E., De Jonghe S., Herdewijn P., Opdenakker G. Gelatin degradation assay reveals MMP-9 inhibitors and function of O-glycosylated domain. World J. Biol. Chem. 2011, 2:14-24.
58. Vandooren J., Geurts N., Martens E., Van den Steen P.E., Opdenakker G. Zymography methods for visualizing hydrolytic enzymes. Nat. Methods 2013, 10:211-220.
59. Vandooren J., Van den Steen P.E., Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit. Rev. Biochem. Mol. Biol. 2013, 48:222-272.
60. Vu T.H., Shipley J.M., Bergers G., Berger J.E., Helms J.A., Hanahan D., Shapiro S.D., Senior R.M., Werb Z. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998, 93:411-422.
61. Weeks B.S., Schnaper H.W., Handy M., Holloway E., Kleinman H.K. Human T lymphocytes synthesize the 92kDa type IV collagenase (gelatinase B). J. Cell. Physiol. 1993, 157:644-649.
62. Wilhelm S.M., Collier I.E., Marmer B.L., Eisen A.Z., Grant G.A., Goldberg G.I. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J. Biol. Chem. 1989, 264:17213-17221.
63. Yong V.W., Power C., Forsyth P., Edwards D.R. Metalloproteinases in biology and pathology of the nervous system. Nat. Rev. Neurosci. 2001, 2:502-511.
64. Zhou H., Bernhard E.J., Fox F.E., Billings P.C. Induction of metalloproteinase activity in human T-lymphocytes. Biochim. Biophys. Acta 1993, 1177:174-178.